Korro Bio Confirms Termination of Novo Nordisk Agreement and Reports Q3 Results

Filing content

Korro Bio confirmed the termination of its collaboration with Novo Nordisk, effective February 1, 2027. The company reported $124.8 million in cash and equivalents as of Q3 2026, sufficient to fund operations into the second half of 2028.